Predictors of futile surgery in upfront resectable pancreatic ductal adenocarcinoma. possible targets for neoadjuvant chemotherapy?
- 24 September 2025
- journal article
- Published by Elsevier in Pancreatology
- Vol. 25 (7) , 1149-1158
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- A risk score system including CT features for predicting early recurrence of resectable pancreatic ductal adenocarcinoma after radical resection: a dual-center retrospective studyEuropean Radiology, 2025
- The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter studyAnnals of Oncology, 2025
- Futility of Up-Front Resection for Anatomically Resectable Pancreatic CancerJAMA Surgery, 2024
- Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9European Radiology, 2023
- Efficacy of Perioperative Chemotherapy for Resectable Pancreatic AdenocarcinomaJAMA Oncology, 2021
- Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosisCancer Epidemiology, 2020
- Patterns of Recurrence After Resection of Pancreatic Ductal AdenocarcinomaJAMA Surgery, 2019
- A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?Journal of Gastrointestinal Surgery, 2018
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer ResectionJAMA, 2010
- Redefining the R1 resection in pancreatic cancerBritish Journal of Surgery, 2006